-
-
-
-
-
-
-
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Stifel on Neumora Therapeutics (NMRA): ' it's hard to have much conviction in the mechanism in MDD'
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Neumora Therapeutics (NMRA), PT $7
-
-
-
-
-
-
-
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
-
-
-
-
1,219,388 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

